Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Pharmaceuticals and Technology Converge in 'Fantastic Voyage' to Fight Disease

8/5/2016

0 Comments

 
London ― Reuters reports that the line between pharmaceuticals and technology is blurring as companies join forces to tackle chronic diseases using high-tech devices that combine biology, software and hardware.
 
GlaxoSmithKline and Google parent Alphabet are the latest to share expertise, unveiling a new joint company on Monday that aims to market bioelectronic devices to fight illness by attaching to individual nerves.
 
The plan to wrap a grain-sized electronic collar around nerves sounds like something from 'Fantastic Voyage', the 1966 sci-fi film in which a submarine is shrunk to fix an injured scientist's brain, yet GSK and Alphabet are not alone in pushing the boundaries in medical tech in this way.
 
U.S. biotech firms Setpoint Medical and EnteroMedics have already shown the early benefits of bioelectronics both to tackle inflammatory diseases like rheumatoid arthritis and suppress appetite in the obese.
 
Others are miniaturizing technology in different ways.
​Medtronic, for example, sells a well-established camera-in-a-pill as an alternative to colonoscopies, while Proteus Digital Technology is working with drugmakers on pills with embedded microchips that measure drug usage.
 
Makers of lung treatments are racing to make smart inhalers.
 
"It's an area that hotting up pretty fast because the technology is moving so fast," said Hilary Thomas, chief medical adviser at KPMG.
 
Many of the world's biggest pharmaceutical companies have turned to tech experts at Alphabet, including Swiss-based Novartis, which is working with the U.S. group on a smart contact lens with an embedded glucose sensor to help monitor diabetes.
 
Novartis Chief Executive Joe Jimenez has said that the combination of pharmaceuticals and technology will eventually be "front and center" in disease management.
 
Sanofi also has a diabetes deal with Alphabet, while Biogen is working with the tech giant to study the progression of multiple sclerosis.
 
Certainly, many technology companies are pushing hard into the healthcare arena, especially when it comes to finding new ways for patients to monitor their own health and track chronic conditions using smart devices.
 
Businesses such as Apple and Samsung Electronics, along with Alphabet, are all trying to find health-related applications for a new wave of wearable products.
 
Technology and pharmaceutical companies alike believe accurate monitoring using wearables will dovetail with a drive to offer so-called value-based healthcare.
 
The aim is to prove that medicines can keep large groups of patients healthy, thereby improving their appeal to cost-conscious insurers. That gives drugmakers a major incentive to offer services that go beyond routine drug prescriptions.
 
For the full story published in The New York Times, click here.
 
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Powered by Create your own unique website with customizable templates.